India · Delayed Price · Currency is INR Titan Biotech Statistics
Total Valuation
Titan Biotech has a market cap or net worth of INR 17.94 billion. The enterprise value is 17.97 billion.
| Market Cap | 17.94B |
| Enterprise Value | 17.97B |
Important Dates
The last earnings date was Saturday, May 30, 2026.
| Earnings Date | May 30, 2026 |
| Ex-Dividend Date | Sep 19, 2025 |
Share Statistics
Titan Biotech has 41.32 million shares outstanding. The number of shares has increased by 0.04% in one year.
| Current Share Class | 41.32M |
| Shares Outstanding | 41.32M |
| Shares Change (YoY) | +0.04% |
| Shares Change (QoQ) | -0.09% |
| Owned by Insiders (%) | 8.72% |
| Owned by Institutions (%) | n/a |
| Float | 13.13M |
Valuation Ratios
The trailing PE ratio is 60.04.
| PE Ratio | 60.04 |
| Forward PE | n/a |
| PS Ratio | 8.70 |
| PB Ratio | 9.88 |
| P/TBV Ratio | 9.88 |
| P/FCF Ratio | 78.06 |
| P/OCF Ratio | 58.96 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 43.80, with an EV/FCF ratio of 78.23.
| EV / Earnings | 60.15 |
| EV / Sales | 8.72 |
| EV / EBITDA | 43.80 |
| EV / EBIT | 49.77 |
| EV / FCF | 78.23 |
Financial Position
The company has a current ratio of 3.28, with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.28 |
| Quick Ratio | 0.95 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.15 |
| Debt / FCF | 0.25 |
| Interest Coverage | 36.85 |
Financial Efficiency
Return on equity (ROE) is 17.84% and return on invested capital (ROIC) is 13.88%.
| Return on Equity (ROE) | 17.84% |
| Return on Assets (ROA) | 10.83% |
| Return on Invested Capital (ROIC) | 13.88% |
| Return on Capital Employed (ROCE) | 17.92% |
| Weighted Average Cost of Capital (WACC) | 1.36% |
| Revenue Per Employee | 4.42M |
| Profits Per Employee | 639,940 |
| Employee Count | 467 |
| Asset Turnover | 1.06 |
| Inventory Turnover | 1.81 |
Taxes
In the past 12 months, Titan Biotech has paid 107.27 million in taxes.
| Income Tax | 107.27M |
| Effective Tax Rate | 26.41% |
Stock Price Statistics
The stock price has increased by +411.73% in the last 52 weeks. The beta is -0.53, so Titan Biotech's price volatility has been lower than the market average.
| Beta (5Y) | -0.53 |
| 52-Week Price Change | +411.73% |
| 50-Day Moving Average | 454.09 |
| 200-Day Moving Average | 287.84 |
| Relative Strength Index (RSI) | 45.43 |
| Average Volume (20 Days) | 30,157 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Titan Biotech had revenue of INR 2.06 billion and earned 298.85 million in profits. Earnings per share was 7.23.
| Revenue | 2.06B |
| Gross Profit | 1.10B |
| Operating Income | 336.78M |
| Pretax Income | 406.13M |
| Net Income | 298.85M |
| EBITDA | 386.04M |
| EBIT | 336.78M |
| Earnings Per Share (EPS) | 7.23 |
Balance Sheet
The company has 18.73 million in cash and 57.07 million in debt, with a net cash position of -38.34 million or -0.93 per share.
| Cash & Cash Equivalents | 18.73M |
| Total Debt | 57.07M |
| Net Cash | -38.34M |
| Net Cash Per Share | -0.93 |
| Equity (Book Value) | 1.82B |
| Book Value Per Share | 43.94 |
| Working Capital | 592.80M |
Cash Flow
In the last 12 months, operating cash flow was 304.21 million and capital expenditures -74.44 million, giving a free cash flow of 229.77 million.
| Operating Cash Flow | 304.21M |
| Capital Expenditures | -74.44M |
| Depreciation & Amortization | 49.25M |
| Net Borrowing | 29.11M |
| Free Cash Flow | 229.77M |
| FCF Per Share | 5.56 |
Margins
Gross margin is 53.35%, with operating and profit margins of 16.33% and 14.49%.
| Gross Margin | 53.35% |
| Operating Margin | 16.33% |
| Pretax Margin | 19.70% |
| Profit Margin | 14.49% |
| EBITDA Margin | 18.72% |
| EBIT Margin | 16.33% |
| FCF Margin | 11.14% |
Dividends & Yields
This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 0.12%.
| Dividend Per Share | 0.50 |
| Dividend Yield | 0.12% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 5.53% |
| Buyback Yield | -0.04% |
| Shareholder Yield | 0.08% |
| Earnings Yield | 1.67% |
| FCF Yield | 1.28% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on February 20, 2026. It was a forward split with a ratio of 5.
| Last Split Date | Feb 20, 2026 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |